We also assessed a range of secondary efficacy indicators after the 28-day treatment, including lipid levels, fasting glucose levels and insulin, inflammatory cytokines, and obesity parameters. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.